DRKS00033663尚未招募不适用
Multi-centric Validation of the FAST4D Score in Emergency medical service STroke dEtection and Capability to predict large vessel occlusion eligible for endovascular Treatment - FAST4Detect
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients who are referred to the emergency room with suspected stroke in one of the participating clinics. These patients receive a patient allocation code (PZC) from the emergency services, which they use to register electronically at the destination clinic. There are 3 codes for stroke, depending on the onset of symptoms. All patients with these codes are recorded: 421/422/423 (Apoplexy/TIA/Hemorrhage”)
- •In order to record patients who are not assigned as having a stroke but were diagnosed with a stroke during diagnostics, all patients with the corresponding discharge diagnosis are also recorded.
- •For the retrospective control group, the identification of patients is carried out in the same way by screening the patients who were suspected of having a stroke in the emergency room during this time and after the discharge diagnosis. The retrospective data collection will cover the year 2023.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
ong-term clinical safety study to evaluate the risk of actinic keratosis progressing to skin cancer following treatment of the face or scalp with tirbanibulin 10 mg/g ointment and in comparison to diclofenac 3% gel in adult patients. Tirbanibulin and diclofenac are used to treat adults with actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.Actinic Keratosis on the Face or ScalpMedDRA version: 20.0Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-004349-18-PLAlmirall, S.A.450
进行中（未招募）
1 期
ong-term clinical safety study to evaluate the risk of actinic keratosis progressing to skin cancer following treatment of the face or scalp with tirbanibulin 10 mg/g ointment and in comparison to diclofenac 3% gel in adult patients. Tirbanibulin and diclofenac are used to treat adults with actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.EUCTR2021-004349-18-ESAlmirall, S.A.540
招募中
4 期
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or ScalpActinic Keratosis2024-514394-22-00Almirall S.A.418
进行中（未招募）
1 期
ong-term clinical safety study to evaluate the risk of actinic keratosis progressing to skin cancer following treatment of the face or scalp with tirbanibulin 10 mg/g ointment and in comparison to diclofenac 3% gel in adult patients. Tirbanibulin and diclofenac are used to treat adults with actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.Actinic Keratosis on the Face or ScalpMedDRA version: 20.0Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-004349-18-FRAlmirall, S.A.540
进行中（未招募）
1 期
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or ScalpActinic KeratosisCTIS2024-514394-22-00Almirall S.A.450